MTOR and breast carcinoma: Other mTOR inhibitors are deforolimus (an investigational agent in the management of sarcoma and breast cancer), zotarolimus (used as a coating in stents), ridaforolimus (used in eluting stents and in advanced malignancies) and temsirolimus (used in kidney cancer and under investigation for lymphoma, breast cancer, and other tumours).